Shots:
- QIAGEN has launched the CE-IVDR certified QIAstat-Dx BCID GPF Plus AMR Panel, marking its entry into syndromic testing for bloodstream infections
- The panel identifies 20 gram-positive bacterial & fungal pathogen targets & 10 antimicrobial resistance markers, delivering results in ~1 hour to support rapid clinical decision-making & antimicrobial stewardship
- The panel was showcased at ESCMID Global 2026 Congress, with the launch expanding QIAstat-Dx beyond respiratory & CNS testing, plus additional panels, incl. gram-negative targets, are in development
Ref: Businesswire | Image: QIAGEN | Press Release
Related News: QIAGEN Wins the US FDA Clearance for QIAstat-Dx GI Panels on QIAstat-Dx Rise Syndromic Testing System
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
